KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Liabilities and Shareholders Equity: 2015-2025

Historic Liabilities and Shareholders Equity for CRISPR Therapeutics AG (CRSP) over the last 9 years, with Sep 2025 value amounting to $2.2 billion.

  • CRISPR Therapeutics AG's Liabilities and Shareholders Equity fell 0.48% to $2.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $8.7 billion, marking a year-over-year decrease of 6.28%. This contributed to the annual value of $2.2 billion for FY2024, which is 0.56% up from last year.
  • According to the latest figures from Q3 2025, CRISPR Therapeutics AG's Liabilities and Shareholders Equity is $2.2 billion, which was up 10.62% from $2.0 billion recorded in Q2 2025.
  • In the past 5 years, CRISPR Therapeutics AG's Liabilities and Shareholders Equity registered a high of $2.9 billion during Q2 2021, and its lowest value of $2.0 billion during Q1 2021.
  • Over the past 3 years, CRISPR Therapeutics AG's median Liabilities and Shareholders Equity value was $2.2 billion (recorded in 2024), while the average stood at $2.2 billion.
  • Per our database at Business Quant, CRISPR Therapeutics AG's Liabilities and Shareholders Equity surged by 177.06% in 2021 and then decreased by 18.49% in 2022.
  • Over the past 5 years, CRISPR Therapeutics AG's Liabilities and Shareholders Equity (Quarterly) stood at $2.8 billion in 2021, then decreased by 18.49% to $2.2 billion in 2022, then declined by 0.60% to $2.2 billion in 2023, then climbed by 0.56% to $2.2 billion in 2024, then declined by 0.48% to $2.2 billion in 2025.
  • Its Liabilities and Shareholders Equity stands at $2.2 billion for Q3 2025, versus $2.0 billion for Q2 2025 and $2.2 billion for Q1 2025.